Arcturus Therapeutics (NASDAQ:ARCT) Earns "Sell (D-)" Rating from Weiss Ratings

Key Points

• Arcturus Therapeutics has received a "Sell (D-)" rating from Weiss Ratings, reaffirming bearish sentiment about the stock.
• Analysts have mixed opinions on the stock, with ratings ranging from "Strong Buy" to "Sell," and a consensus rating of "Moderate Buy" with an average target price of $31.71.
• The company's stock recently traded at $11.22, down from a 52-week high of $24.17, reflecting significant volatility in its market performance.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by stock analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Several other equities research analysts have also weighed in on ARCT. Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a report on Wednesday, July 2nd. Leerink Partners reduced their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an "outperform" rating on the stock in a research note on Friday, August 22nd. HC Wainwright reissued a "neutral" rating and issued a $12.00 price objective (down previously from $60.00) on shares of Arcturus Therapeutics in a research note on Friday. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Citigroup lowered shares of Arcturus Therapeutics from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $49.00 to $12.00 in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Arcturus Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $31.71.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock traded down $0.78 on Friday, reaching $11.22. The stock had a trading volume of 3,844,222 shares, compared to its average volume of 642,428. The stock has a market cap of $304.68 million, a P/E ratio of -5.03 and a beta of 2.39. Arcturus Therapeutics has a fifty-two week low of $8.04 and a fifty-two week high of $24.17. The business's 50-day moving average price is $18.88 and its two-hundred day moving average price is $14.74.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million during the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. As a group, equities analysts forecast that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. lifted its position in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 738 shares during the period. US Bancorp DE lifted its position in Arcturus Therapeutics by 218.9% during the 1st quarter. US Bancorp DE now owns 3,393 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 2,329 shares during the period. BNP Paribas Financial Markets lifted its position in Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 2,586 shares during the period. SG Americas Securities LLC acquired a new position in Arcturus Therapeutics during the 3rd quarter valued at about $147,000. Finally, Strs Ohio acquired a new position in Arcturus Therapeutics during the 1st quarter valued at about $89,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.